GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Enzo Biochem Inc (NYSE:ENZ) » Definitions » Long-Term Debt & Capital Lease Obligation

Enzo Biochem (Enzo Biochem) Long-Term Debt & Capital Lease Obligation : $3.02 Mil (As of Jan. 2024)


View and export this data going back to 1980. Start your Free Trial

What is Enzo Biochem Long-Term Debt & Capital Lease Obligation?

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Enzo Biochem's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $3.02 Mil.

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligation divides by its Total Assets. Enzo Biochem's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $3.02 Mil. Enzo Biochem's Total Assets for the quarter that ended in Jan. 2024 was $99.08 Mil. Enzo Biochem's LT-Debt-to-Total-Asset for the quarter that ended in Jan. 2024 was 0.03.

Enzo Biochem's LT-Debt-to-Total-Asset declined from Jan. 2023 (0.15) to Jan. 2024 (0.03). It may suggest that Enzo Biochem is progressively becoming less dependent on debt to grow their business.


Enzo Biochem Long-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Enzo Biochem's Long-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzo Biochem Long-Term Debt & Capital Lease Obligation Chart

Enzo Biochem Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Long-Term Debt & Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.18 21.33 19.02 8.13 3.43

Enzo Biochem Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Long-Term Debt & Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.42 10.98 3.43 3.19 3.02

Enzo Biochem Long-Term Debt & Capital Lease Obligation Calculation

Long-Term Debt is the debt due more than 12 months in the future. The debt can be owed to banks or bondholders. Some companies issue bonds to investors and pay interest on the bonds.

Long-Term Capital Lease Obligation represents the total liability for long-term leases lasting over one year. It's amount equal to the present value (the principal) at the beginning of the lease term less lease payments during the lease term.

The interest paid on companies' debt is reflected in the income statement as interest expense. If a company has too much debt and it cannot serve the interest payment on the debt or repay the matured debt, the company risks bankruptcy. Peter Lynch famously said: A company that does not have debt cannot go bankrupt.

A company's long term debt may have different dates of maturity and interest rates, depending on the terms.

Usually a company issues long term debt to pay for its capital expenditures. Borrowing allows the company to do things that otherwise cannot be done with only the capital it has. But debt can be risky.


Enzo Biochem  (NYSE:ENZ) Long-Term Debt & Capital Lease Obligation Explanation

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Enzo Biochem's LT-Debt-to-Total-Asset ratio for the quarter that ended in Jan. 2024 is calculated as:

LT-Debt-to-Total-Asset (Q: Jan. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Jan. 2024 )/Total Assets (Q: Jan. 2024 )
=3.019/99.077
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Buffett says that durable competitive advantages carry little to no long-term debt because the company is so profitable that even expansions or acquisitions are self financed.

We are interested in long term debt load for the last ten years. If the ten years of operation show little to no long term debt, then the company has some kind of strong competitive advantage.

Warren Buffett's historic purchases indicate that on any given year, the company should have sufficient yearly net earnings to pay all long term within 3 or 4 year earnings period. (e.g. Coke + Moody's = 1yr)

Companies with enough earning power to pay long term debt in less than 3 or 4 years is a good candidate in our search for long term competitive advantage.

BUT, these companies are targets for leveraged buy outs, which saddles the business with long term debt.

If all else indicates the company has a moat, but it has ton of debt, a leveraged buyout may have created the debt. In these cases the company's bonds offer the better bet, in that the company’s earnings power is focused on paying off the debt and not growth.

Important: little or no long term debt often means a Good Long Term Bet


Enzo Biochem Long-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Enzo Biochem's Long-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzo Biochem (Enzo Biochem) Business Description

Industry
Traded in Other Exchanges
Address
527 Madison Avenue, New York, NY, USA, 10022
Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. It focuses on delivering and applying its technology to produce products and services to allow its customers to meet their clinical needs. The company has Enzo clinical labs, Enzo life sciences, Enzo therapeutics operating segments. It derives the majority of its revenues from the Clinical lab's segment.
Executives
Steven J Pully director 9800 RICHMOND AVE, SUITE 700, HOUSTON TX 77042
James G. Wolf 10 percent owner 105, FLYWAY DRIVE, KIAWAH ISLAND SC 29455
Hamid Erfanian officer: Chief Executive Officer 527 MADISON AVENUE, NEW YORK NY 10022
Patricia Eckert officer: Interim CFO C/O ENZO BIOCHEM, INC., 81 EXECUTIVE BLVD, SUITE 3, FARMINGDALE NY 11735
Kara Cannon officer: Chief Operating Officer 527 MADISON AVE, NEW YORK NY 10022
Bradley Louis Radoff director 2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
David Bench officer: CHIEF FINANCIAL OFFICER ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Harbert Discovery Fund, Lp 10 percent owner HARBERT DISCOVERY FUND GP, LLC, 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Ian B. Walters director ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Mary Tagliaferri director 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Clemens Peter J Iv 10 percent owner 2383 N. BERRY'S CHAPEL RD., FRANKLIN TN 37069
Rebecca J. Fischer director ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Fabian Blank 10 percent owner, other: See Remarks ROEMERSTRASSE 6, BAD BERTRICH 2M 56864
Harbert Management Corp 10 percent owner 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Harbert Discovery Co-investment Fund I Gp, Llc 10 percent owner 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203